ATOSSA THERAPEUTICS INC (ATOS) Stock Fundamental Analysis

NASDAQ:ATOS • US04962H7044

4.27 USD
+0.06 (+1.43%)
At close: Feb 25, 2026
4.3 USD
+0.03 (+0.7%)
After Hours: 2/25/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, ATOS scores 2 out of 10 in our fundamental rating. ATOS was compared to 521 industry peers in the Biotechnology industry. While ATOS has a great health rating, there are worries on its profitability. ATOS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ATOS has reported negative net income.
  • In the past year ATOS has reported a negative cash flow from operations.
  • ATOS had negative earnings in each of the past 5 years.
  • ATOS had a negative operating cash flow in each of the past 5 years.
ATOS Yearly Net Income VS EBIT VS OCF VS FCFATOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • ATOS's Return On Assets of -52.02% is in line compared to the rest of the industry. ATOS outperforms 48.37% of its industry peers.
  • With a decent Return On Equity value of -60.62%, ATOS is doing good in the industry, outperforming 60.84% of the companies in the same industry.
Industry RankSector Rank
ROA -52.02%
ROE -60.62%
ROIC N/A
ROA(3y)-28.82%
ROA(5y)-30.64%
ROE(3y)-30.53%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ATOS Yearly ROA, ROE, ROICATOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ATOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATOS Yearly Profit, Operating, Gross MarginsATOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • ATOS has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ATOS has more shares outstanding
  • ATOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ATOS Yearly Shares OutstandingATOS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ATOS Yearly Total Debt VS Total AssetsATOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • ATOS has an Altman-Z score of -3.93. This is a bad value and indicates that ATOS is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -3.93, ATOS is in line with its industry, outperforming 43.38% of the companies in the same industry.
  • ATOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.93
ROIC/WACCN/A
WACCN/A
ATOS Yearly LT Debt VS Equity VS FCFATOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • ATOS has a Current Ratio of 6.77. This indicates that ATOS is financially healthy and has no problem in meeting its short term obligations.
  • ATOS has a Current ratio of 6.77. This is in the better half of the industry: ATOS outperforms 68.71% of its industry peers.
  • ATOS has a Quick Ratio of 6.77. This indicates that ATOS is financially healthy and has no problem in meeting its short term obligations.
  • ATOS has a Quick ratio of 6.77. This is in the better half of the industry: ATOS outperforms 68.91% of its industry peers.
Industry RankSector Rank
Current Ratio 6.77
Quick Ratio 6.77
ATOS Yearly Current Assets VS Current LiabilitesATOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for ATOS have decreased strongly by -780.00% in the last year.
EPS 1Y (TTM)-780%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1650%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -102.61% on average over the next years. This is quite bad
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-1721.43%
EPS Next 2Y-357.01%
EPS Next 3Y-187.16%
EPS Next 5Y-102.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATOS Yearly Revenue VS EstimatesATOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
ATOS Yearly EPS VS EstimatesATOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ATOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ATOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATOS Price Earnings VS Forward Price EarningsATOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATOS Per share dataATOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • A cheap valuation may be justified as ATOS's earnings are expected to decrease with -187.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-357.01%
EPS Next 3Y-187.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ATOS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATOSSA THERAPEUTICS INC

NASDAQ:ATOS (2/25/2026, 8:00:01 PM)

After market: 4.3 +0.03 (+0.7%)

4.27

+0.06 (+1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-23
Inst Owners19.46%
Inst Owner Change13.47%
Ins Owners0.04%
Ins Owner Change84.6%
Market Cap36.76M
Revenue(TTM)N/A
Net Income(TTM)-30.18M
Analysts82
Price TargetN/A
Short Float %N/A
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.14%
Min EPS beat(2)-19.35%
Max EPS beat(2)-2.94%
EPS beat(4)2
Avg EPS beat(4)3.45%
Min EPS beat(4)-19.35%
Max EPS beat(4)22.6%
EPS beat(8)4
Avg EPS beat(8)-0.71%
EPS beat(12)7
Avg EPS beat(12)1.15%
EPS beat(16)11
Avg EPS beat(16)4.28%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.1%
EPS NQ rev (1m)-1400%
EPS NQ rev (3m)-1400%
EPS NY rev (1m)-1400%
EPS NY rev (3m)-1420.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-2.2
EYN/A
EPS(NY)-4.39
Fwd EYN/A
FCF(TTM)-3.05
FCFYN/A
OCF(TTM)-3.05
OCFYN/A
SpS0
BVpS5.78
TBVpS5.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.02%
ROE -60.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.82%
ROA(5y)-30.64%
ROE(3y)-30.53%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.95%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.77
Quick Ratio 6.77
Altman-Z -3.93
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)157.54%
Cap/Depr(5y)108.53%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-780%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1650%
EPS Next Y-1721.43%
EPS Next 2Y-357.01%
EPS Next 3Y-187.16%
EPS Next 5Y-102.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.99%
OCF growth 3YN/A
OCF growth 5YN/A

ATOSSA THERAPEUTICS INC / ATOS FAQ

What is the fundamental rating for ATOS stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATOS.


Can you provide the valuation status for ATOSSA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ATOSSA THERAPEUTICS INC (ATOS). This can be considered as Overvalued.


Can you provide the profitability details for ATOSSA THERAPEUTICS INC?

ATOSSA THERAPEUTICS INC (ATOS) has a profitability rating of 1 / 10.


How financially healthy is ATOSSA THERAPEUTICS INC?

The financial health rating of ATOSSA THERAPEUTICS INC (ATOS) is 7 / 10.